CR20210330A - ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325) - Google Patents

ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325)

Info

Publication number
CR20210330A
CR20210330A CR20210330A CR20210330A CR20210330A CR 20210330 A CR20210330 A CR 20210330A CR 20210330 A CR20210330 A CR 20210330A CR 20210330 A CR20210330 A CR 20210330A CR 20210330 A CR20210330 A CR 20210330A
Authority
CR
Costa Rica
Prior art keywords
antibodies
antibodies binding
methods
present
relates
Prior art date
Application number
CR20210330A
Other languages
English (en)
Inventor
Wolfgang Richter
Valeria G Nicolini
Inja Waldhauer
Thomas Hofer
Anne Freimoser-Grundschober
Ekkehard Moessner
Pablo Umaña
Halina Trochanowska
Alexander Knaupp
Ralf Hosse
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20210330A publication Critical patent/CR20210330A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

La presente invención se refiere de manera general a anticuerpos que se unen a CD3, incluyendo anticuerpos multiespecíficos, por ejemplo, para linfocitos T activadores. Además, la presente invención se refiere a polinucleótidos que codifican dichos anticuerpos y a vectores y células hospedadoras que comprenden dichos polinucleótidos. La invención se refiere además a métodos para producir los anticuerpos y a métodos para usarlos en el tratamiento de enfermedades
CR20210330A 2018-12-21 2019-12-19 ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325) CR20210330A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18214994 2018-12-21
PCT/EP2019/086144 WO2020127619A1 (en) 2018-12-21 2019-12-19 Antibodies binding to cd3

Publications (1)

Publication Number Publication Date
CR20210330A true CR20210330A (es) 2021-07-20

Family

ID=64755342

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20210330A CR20210330A (es) 2018-12-21 2019-12-19 ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325)
CR20210325A CR20210325A (es) 2018-12-21 2019-12-19 Anticuerpos que se unen a cd3

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20210325A CR20210325A (es) 2018-12-21 2019-12-19 Anticuerpos que se unen a cd3

Country Status (20)

Country Link
US (4) US11672858B2 (es)
EP (1) EP3897847A1 (es)
JP (1) JP7061733B2 (es)
KR (1) KR20210094588A (es)
CN (1) CN113621062A (es)
AR (1) AR117727A1 (es)
AU (2) AU2019410075B2 (es)
BR (1) BR112021011939A2 (es)
CA (1) CA3115020A1 (es)
CL (2) CL2021001506A1 (es)
CO (2) CO2021011065A2 (es)
CR (2) CR20210330A (es)
IL (1) IL283939A (es)
MA (1) MA54514A (es)
MX (1) MX2021007307A (es)
MY (1) MY194642A (es)
PE (1) PE20211603A1 (es)
SG (3) SG10202105790QA (es)
TW (2) TWI829831B (es)
WO (1) WO2020127619A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
ES2764111T3 (es) * 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
US11672858B2 (en) 2018-12-21 2023-06-13 Hoffmann-La Roche Inc. Bispecific antibody molecules binding to CD3 and TYRP-1
JP2022543553A (ja) * 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
MX2022016069A (es) * 2020-06-19 2023-02-02 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19.
MX2022015204A (es) * 2020-06-19 2023-01-05 Hoffmann La Roche Anticuerpos que se unen a cd3.
WO2021255146A1 (en) * 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
AU2021291005A1 (en) * 2020-06-19 2023-01-05 F. Hoffmann-La Roche Ag Antibodies binding to CD3 and FolR1
AR122659A1 (es) * 2020-06-19 2022-09-28 Hoffmann La Roche Anticuerpos biespecíficos para linfocitos t activados por proteasa
IL303656A (en) 2020-12-17 2023-08-01 Hoffmann La Roche ANTI-HLA-G antibodies and their use
US20220229062A1 (en) * 2021-01-21 2022-07-21 Diagnostic Biosystems Method for rapid immunohistochemical detection of an antigen from a biological sample
EP4304724A1 (en) 2021-03-09 2024-01-17 F. Hoffmann-La Roche AG Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
WO2022263507A1 (en) 2021-06-17 2022-12-22 Boehringer Ingelheim International Gmbh Novel tri-specific binding molecules
WO2023094569A1 (en) 2021-11-26 2023-06-01 F. Hoffmann-La Roche Ag Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
WO2024027120A1 (en) * 2022-08-05 2024-02-08 Shanghai Kaijin Biotechnology , Ltd Multi-specific polypeptide complexes
WO2024040127A2 (en) * 2022-08-16 2024-02-22 Northwestern University Anti-tyrp1 bi-specific t cell engaging protein for treatment of tyrp1-expressing melanoma

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US830930A (en) 1905-11-22 1906-09-11 E & T Fairbanks & Co Weighing-scale.
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
RO118524B1 (ro) 1992-11-13 2003-06-30 Idec Pharmaceuticals Corp San Metoda pentru tratarea unei tulburari legata de celulele b
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2003505082A (ja) 1999-07-26 2003-02-12 ジェネンテック・インコーポレーテッド 新規なポリヌクレオチドとその使用法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2385347C (en) 1999-10-04 2009-12-15 Medicago Inc. Method for regulating transcription of foreign genes
IL151853A0 (en) 2000-04-11 2003-04-10 Genentech Inc Multivalent antibodies and uses therefor
KR20040054669A (ko) 2001-08-03 2004-06-25 글리카트 바이오테크놀로지 아게 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
CN100423777C (zh) 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
CA2481657A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
WO2003085102A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose
JP4351674B2 (ja) 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体とその使用法およびその使用
EP2264151B1 (en) 2003-01-22 2016-04-20 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
RU2005141512A (ru) 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
BR122019012028B1 (pt) 2004-04-13 2023-09-26 F. Hoffmann-La Roche Ag Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
RU2412947C2 (ru) 2004-09-23 2011-02-27 Дженентек, Инк. Антитела, сконструированные на основе цистеинов, и их конъюгаты
CN101115773B (zh) 2005-02-07 2015-06-10 罗氏格黎卡特股份公司 结合egfr的抗原结合分子,编码它的载体,及其应用
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
PL2520590T3 (pl) 2007-04-03 2019-02-28 Amgen Research (Munich) Gmbh Domena wiążąca wykazująca krzyżową swoistość gatunkową
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
CA2757931C (en) 2009-04-07 2019-03-26 Roche Glycart Ag Trivalent, bispecific antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
BRPI1007602A2 (pt) 2009-05-27 2016-02-16 Hoffmann La Roche "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia"
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
PT2519543T (pt) 2009-12-29 2016-10-07 Emergent Product Dev Seattle Proteínas de ligação de heterodímero e suas utilizações
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
WO2011156328A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
WO2012130831A1 (en) 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
DK2748202T3 (en) 2011-08-23 2018-09-17 Roche Glycart Ag BISPECIFIC ANTI-BINDING MOLECULES
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
PL3321286T3 (pl) 2011-08-23 2021-05-31 Roche Glycart Ag Dwuswoiste cząsteczki wiążące antygen aktywujące limfocyty T
CN104011221B (zh) 2011-12-20 2019-01-08 米迪缪尼有限公司 用于双特异性抗体支架的经修饰的多肽
JP6152120B2 (ja) 2012-02-15 2017-06-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体に基づくアフィニティークロマトグラフィー
KR20230091201A (ko) 2012-04-20 2023-06-22 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
AU2013258834B2 (en) * 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
JP6133444B2 (ja) 2013-02-26 2017-05-24 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2015018527A1 (en) * 2013-08-07 2015-02-12 Affimed Therapeutics Ag ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII
CA3204788A1 (en) 2013-12-20 2015-06-25 Genentech, Inc. Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
WO2016016299A1 (en) 2014-07-29 2016-02-04 F. Hoffmann-La Roche Ag Multispecific antibodies
CN107074973A (zh) * 2014-07-29 2017-08-18 辉瑞大药厂 用于癌症免疫疗法的EGFRvIII特异性嵌合抗原受体
JP6749312B2 (ja) * 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 最適化された種間特異的二重特異性単鎖抗体コンストラクト
EA038958B1 (ru) 2014-08-04 2021-11-15 Ф. Хоффманн-Ля Рош Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
RU2017107502A (ru) 2014-09-12 2018-10-12 Дженентек, Инк. Антитела и конъюгаты, сконструированные введением цистеина
HUE051715T2 (hu) * 2014-11-20 2021-03-29 Hoffmann La Roche T-sejt-aktiváló bispecifikus antigénkötõ molekulák a FolR1 és CD3 ellen
SI3221355T1 (sl) * 2014-11-20 2021-01-29 F. Hoffmann-La Roche Ag Kombinirano zdravljenje z bispecifičnimi molekulami CD3, ki aktivirajo celice T in vežejo antigene in folatni receptor 1 (FoIR1) ter antagonisti za vezavo osi PD-1
EP3286227A2 (en) 2015-04-24 2018-02-28 F. Hoffmann-La Roche AG Multispecific antigen-binding proteins
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
WO2017055391A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
EP3356409A2 (en) * 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific t cell activating antigen binding molecules
AR106201A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
CN114891102A (zh) 2015-10-29 2022-08-12 豪夫迈·罗氏有限公司 抗变体Fc区抗体及使用方法
KR102479606B1 (ko) * 2016-01-21 2022-12-21 화이자 인코포레이티드 상피 성장 인자 수용체 변이체 iii을 표적화하는 키메라 항원 수용체
WO2020127618A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
US11672858B2 (en) 2018-12-21 2023-06-13 Hoffmann-La Roche Inc. Bispecific antibody molecules binding to CD3 and TYRP-1
JP2022543553A (ja) 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
CA3176552A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Immune activating fc domain binding molecules
AU2021291005A1 (en) 2020-06-19 2023-01-05 F. Hoffmann-La Roche Ag Antibodies binding to CD3 and FolR1
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
MX2022016069A (es) 2020-06-19 2023-02-02 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19.
IL303656A (en) 2020-12-17 2023-08-01 Hoffmann La Roche ANTI-HLA-G antibodies and their use

Also Published As

Publication number Publication date
CO2021008568A2 (es) 2021-07-30
CN113621062A (zh) 2021-11-09
AU2022206732A1 (en) 2022-09-29
EP3897847A1 (en) 2021-10-27
AU2019410075A1 (en) 2021-04-15
MX2021007307A (es) 2021-07-07
KR20210094588A (ko) 2021-07-29
TW202212361A (zh) 2022-04-01
IL283939A (en) 2021-07-29
CL2021001506A1 (es) 2021-12-24
CN113195056A (zh) 2021-07-30
AR117727A1 (es) 2021-08-25
US11591397B2 (en) 2023-02-28
CA3115020A1 (en) 2020-06-25
US20200270347A1 (en) 2020-08-27
SG10202105790QA (en) 2021-07-29
TW202039566A (zh) 2020-11-01
AU2019410075B2 (en) 2022-08-25
US11672858B2 (en) 2023-06-13
SG10202105788SA (en) 2021-06-29
JP2022513493A (ja) 2022-02-08
MA54514A (fr) 2022-03-30
TWI818387B (zh) 2023-10-11
MY194642A (en) 2022-12-09
CL2021003132A1 (es) 2022-08-19
JP7061733B2 (ja) 2022-04-28
US20240042022A1 (en) 2024-02-08
BR112021011939A2 (pt) 2021-09-14
WO2020127619A1 (en) 2020-06-25
SG11202102859TA (en) 2021-04-29
US20230277662A1 (en) 2023-09-07
TWI829831B (zh) 2024-01-21
CO2021011065A2 (es) 2021-09-09
CR20210325A (es) 2021-07-20
PE20211603A1 (es) 2021-08-18
US20210403562A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
MY194642A (en) Antibodies binding to cd3
PH12020551211A1 (en) Antibodies binding to gprc5d
MX2022001156A (es) Anticuerpos que se fijan a gprc5d.
PH12018500634A1 (en) Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
MX2017006571A (es) Moleculas de union a antigeno biespecificas activadoras de celulas t.
PH12020551997A1 (en) Psma binding agents and uses thereof
PH12016502505A1 (en) Bispecific t cell activating antigen binding molecules
MX2022001831A (es) Anticuerpos terapeuticos y sus usos.
MX2022007635A (es) Anticuerpos que se unen a hla-a2/mage-a4.
WO2017055388A3 (en) Bispecific t cell activating antigen binding molecules
MX2020009692A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
MX2015010843A (es) Moleculas biespecificas de union al antigeno que activan celulas t.
MX2015010350A (es) Moleculas de union a antigeno biespecificas que activan la celula t.
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
MX2020013122A (es) Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47).
PH12019502274A1 (en) Antibodies binding to steap-1
PH12020550952A1 (en) Antibodies binding to hla-a2/wt1
MX2022015204A (es) Anticuerpos que se unen a cd3.
MX2022007288A (es) Agentes de union a ilt3 y metodos de uso de los mismos.
CR20220637A (es) Anticuerpos que se unen a cd3 y cd19
MX2022003110A (es) Anticuerpos biespecificos contra ceacam5 y cd3.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.